FAK regulates CSC activity in breast cancer, and inhibition of FAK suppresses self-renewal, leading to a reduced tumor size, thereby providing a promising strategy to improve survival by suppressing CSC activity; the approach is especially effective when combined with paclitaxel treatment [98]. Here, PTK2 is linked to breast carcinoma.